Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish

Kynam Capital reduced its Syndax Pharmaceuticals stake by 469,041 shares in Q4, an estimated $8.18 million trade based on the quarter's average closing prices. The report notes an institutional position reduction but provides no ownership percentage or rationale, suggesting a routine portfolio adjustment with limited market implications.

Analysis

Kynam Capital reduced its Syndax Pharmaceuticals stake by 469,041 shares in Q4, an estimated $8.18 million trade based on the quarter's average closing prices. The report notes an institutional position reduction but provides no ownership percentage or rationale, suggesting a routine portfolio adjustment with limited market implications.